Clorazepate Dipotassium

CHEMBL2096631 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

408.9 g/mol

LogP

—

Phase

4

A benzodiazepine prodrug that is converted to active desmethyldiazepam in the stomach, providing anxiolytic, anticonvulsant, and sedative effects. It is used for anxiety disorders, alcohol withdrawal, and as an adjunct in partial seizure management.

分子量

408.9200 g/mol

TPSA

82.60 Å²

治疗领域

Migraine Lymphoma

作用机制

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]

InChI

InChI=1S/C16H11ClN2O3.2K.H2O/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;;;/h1-8,14H,(H,18,20)(H,21,22);;;1H2/q;2*+1;/p-2

Molecular Formula

C16H11ClK2N2O4

HBD / HBA

2 / 5

可旋转键数

1

重原子数

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A benzodiazepine prodrug that is converted to active desmethyldiazepam in the stomach, providing anxiolytic, anticonvulsant, and sedative effects. It is used for anxiety disorders, alcohol withdrawal, and as an adjunct in partial seizure management.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Clorazepate Dipotassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096631. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 167305. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Clorazepate Dipotassium 在 PillFYI 上

结构

快速数据

分子式: C16H11ClK2N2O4

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.